Yüklüyor......

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biomark Res
Asıl Yazarlar: Wu, Yongfeng, Xu, Jinming, Xu, Jiawei, Wang, Yiqing, Wang, Luming, Lv, Wang, Hu, Jian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7146978/
https://ncbi.nlm.nih.gov/pubmed/32308981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00188-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!